TargetMol

BI-2865

Product Code:
 
TAR-T72062
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T72062-1mg1mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T72062-5mg5mg£532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T72062-10mg10mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T72062-25mg25mg£898.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T72062-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T72062-100mg100mg£1,556.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BI-2865 is a non-covalent pan-KRAS inhibitor.BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively.BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants. BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants with an average IC50 value of approximately 140 nM.
Biological Applications:
(1) KRAS-Specific Inhibitors. KRAS inhibitors can bind to the KRAS protein, rendering it in an inactive state. As mentioned earlier, KRASG12C mutant inhibitors (sotorasib & Adagrasib) irreversibly bind to KRAS, marking a pivotal milestone in clinical drug discovery. However, for another common mutation, KRASG12D (found in 33% of KRAS mutant tumors), there are currently no clinical drugs. Several inhibitors targeting KRASG12D are still in the development stage, with MRTX1133 (Catalog No. T9303) being a prominent candidate. Preclinical research results demonstrate the specific inhibitory activity of MRTX1133 in various tumor cell lines carrying the KRASG12D mutation. The drug has received FDA approval for a new drug clinical trial application and entered Phase I/II clinical trials in 2023. Although there is considerable research on KRAS mutations, an effective and widely applicable clinical drug has yet to be found. Hence, new methods are needed to identify a class of novel selective KRAS inhibitors. (2) Pan-KRAS Inhibitors. More than 100 mutation sites have been identified in RAS subtypes, with prominent mutation hotspots at G12, G13, and Q61. However, KRAS-specific inhibitor targets only G12C or G12D mutants, limiting clinical applications. To address these limitations, research teams have begun developing small molecule pan-KRAS inhibitors. Pan-KRAS inhibitors deactivate common KRAS cancer proteins without the need for covalent anchoring to specific mutant amino acids. These inhibitors can prevent reactivation through nucleotide exchange by preferentially targeting the non-active state of KRAS. Representative examples include BI-2865 and its analogue BI-2493.
CAS:
2937327-93-8
Long Description:
BI-2865 is a non-covalent inhibitor with pan-KRAS potential. This inhibitor induces the inactivation of common KRAS oncoproteins (BI-2865 targets KRAS WT, G12C, G12D, G12V, and G13D mutants) without the need for covalent anchoring to specific mutant amino acids.
Molecular Weight:
465.57
Pathway:
GPCR/G Protein|MAPK
Purity:
0.9939
Research Area:
Pan-KRAS Inhibitors
SMILES:
C[C@]1(C2=C(SC(N)=C2C#N)CCC1)C3=NC(=NO3)C=4N=C(O[C@@H](C)[C@@]5(CCCN5C)[H])C=CN4
Target:
Ras

Documents

References

Kim D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619(7968):160-166.